EUVIMEDDécouvrir EUVIMED
CrossrefCarte d’information

Tracing metastatic spread in pediatric solid tumors using copy number and targeted deep sequencing

Natalie Andersson, Michele Ferro, Caroline Jansson, Subhayan Chattopadhyay, Jenny Karlsson, David Gisselsson

The Journal of Pathology · 2025-11 · 267 (3) · 347-365

DOI: 10.1002/path.6472 ↗
RésuméRéférences bibliographiques

Résumé

Abstract The most common cause of death in pediatric cancer patients is a treatment‐resistant tumor, compounded by metastatic spread, making surgery, radiation therapy, and chemotherapy unfeasible as curative treatment options. However, the mechanisms behind metastatic spread in pediatric tumors remain largely unexplored. We conducted whole‐genome copy number profiling on 171 primary tumor and metastases samples from 17 patients with neuroblastoma, Wilms tumor, or gonadal tumors, and performed targeted deep sequencing on a subset. Phylogenetic reconstruction enabled spatiotemporal tracking of subclones. In total, 11 of 17 patients displayed at least one metastasis arising earlier, defined as occurring before the most recent common ancestor in the primary tumor. In eight patients, metastatic spread was observed several times during tumor evolution, with different subclones from the same primary tumor having metastatic capability, even colonizing the same site. Strikingly, dissemination between metastases (intermetastatic spread) occurred in eight of nine patients with metastases in at least two different sites, indicating that this is a common phenomenon in pediatric malignancy. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Des connaissances adaptées à votre travail.

D’un démarrage gratuit à la Research Suite complète, en passant par la recherche bibliographique personnelle.

Voir les tarifs →

Tous les textes intégraux sont-ils inclus ?

Non. Notices, résumés et textes intégraux sont des contenus distincts. La disponibilité dépend de la source, de l’accès ouvert et de vos licences. Une offre EUVIMED ne remplace pas des droits supplémentaires auprès des éditeurs.

Voir les tarifs →